Brand Name
Cuvrior
Generic Name
Trientine Tetrahydrochloride
View Brand Information FDA approval date: September 14, 2022
Classification: Copper Chelator
Form: Tablet
What is Cuvrior (Trientine Tetrahydrochloride)?
CUVRIOR is indicated for the treatment of adult patients with stable Wilson's disease who are de-coppered and tolerant to penicillamine. CUVRIOR is a copper chelator indicated for the treatment of adult patients with stable Wilson's disease who are de-coppered and tolerant to penicillamine.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
There is no clinical trials being done for this treatment